Ray Romano to Host IMF 10th Annual Comedy Celebration & #225; Nov. 5
The IMF's annual Comedy Celebration will take place on Saturday, November 5 at the Wilshire Ebell Theatre. Actor and comedian Ray Romano returns as “Everybody's Most-Loved Host,” with featured performers Bill Burr, Jeff Garlin, Dom Irrera, Larry Miller, Kevin Nealon, JB Smoove, and Fred Willard. Proceeds from the event benefit the Peter Boyle Research Fund and support the Black Swan Research Initiative® (BSRI). Renowned actor Peter Boyle died in 2006 after a four-year battle with myeloma. In celebration of the event's 10th anniversary, the event will honor Loraine Alterman Boyle for her extraordinary work a...
Source: International Myeloma Foundation - October 3, 2016 Category: Hematology Source Type: news

Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selinexor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news

Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selexinor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news

Watch the replay of the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients& Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T ce...
Source: International Myeloma Foundation - September 21, 2016 Category: Hematology Source Type: news

View the slides for the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients& Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T ce...
Source: International Myeloma Foundation - September 21, 2016 Category: Hematology Source Type: news

Kayaker Determined to Help his Mother and Uncle Battle Multiple Myeloma Completes 600-Mile Washington to Alaska Trip
Raised More than $20,000 to Support International Myeloma Foundation Research (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 15, 2016 Category: Hematology Source Type: news

How Research in Iceland Will Help Myeloma Patients Everywhere
As myeloma researchers at the University of Iceland prepare to launch the exciting iStopMM project, IMF Chairman Dr. Brian Durie examines the benefits this Black Swan Research Initiative® project will generate for the rest of the world: learning, screening, and treating to achieve the best outcomes for myeloma patients everywhere. To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 8, 2016 Category: Hematology Source Type: news

Tune in to the FREE "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients& Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T ce...
Source: International Myeloma Foundation - September 2, 2016 Category: Hematology Source Type: news

Expanding Our Knowledge About Daratumumab and More
Three important new reports are shedding light on how daratumumab works, reports IMF Chairman Dr. Brian Durie in his blog this week. “Our understanding of its benefits—when used alone and in combinations—is evolving rapidly.” But is treatment outpacing reimbursement? Also, this week, Dr. Durie touches on cancer in 9/11 responders, a study that suggests social status may affect outcomes, and a new bestseller that explores the science-fiction-sounding “microbiome.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 25, 2016 Category: Hematology Source Type: news

The Most Important Questions Facing Myeloma Experts in 2016
Close to one hundred members of the International Myeloma Working Group (IMWG) gathered in Copenhagen from June 7th to 9th, just prior to the European Hematology Association (EHA) meeting, for the seventh annual IMWG Summit. This important and prestigious meeting allows myeloma experts from around the globe to discuss pressing issues and to set an agenda of publications, clinical trials, and advocacy efforts for the coming year. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 17, 2016 Category: Hematology Source Type: news

Myeloma Experts of the IMWG Tackle Soaring Costs of Care
Recognizing our responsibility to lead the way in addressing costs effectively, members of the International Myeloma Working Group (IMWG), the research arm of the IMF, launched a plan of action at a special session of the June 2016 annual meeting held in Copenhagen this year. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 16, 2016 Category: Hematology Source Type: news

Takeda Receives Marketing Authorization in Canada for NINLARO ™ (ixazomib) in Relapsed/Refractory Multiple Myeloma
NINLARO™ is the first and only oral proteasome inhibitor approved to provide a new treatment option for adult patients living with multiple myeloma in Canada who have received at least one prior therapy (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 8, 2016 Category: Hematology Source Type: news

NLB New Publications and Resources
Scroll down to learn more. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 4, 2016 Category: Hematology Source Type: news

The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016
  New Categories of Minimal Residual Disease (MRD) Negativity  Provide Clinical Trial Endpoints and Framework for Cure (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 27, 2016 Category: Hematology Source Type: news

Daratumumab (DARZALEX & #174;) Granted Breakthrough Therapy Designation by U.S. FDA for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma
FDA action underscores potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for patients who have received at least one prior therapy. Marks the second Breakthrough Therapy Designation for daratumumab (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 26, 2016 Category: Hematology Source Type: news

IMF's Black Swan Research Initiative & #174;: ASCENT Trial
Dr. Shaji Kumar of the Mayo Clinic in Rochester, Minnesota, discusses the exciting new Black Swan Research Initiative & reg; clinical trial: ASCENT, which stands for Aggressive Smoldering Cure Evaluating Novel Rx Transplant. In the ASCENT trial (which will begin enrolling patients later this year), high-risk smoldering myeloma patients will receive intense therapy for two years. Dr. Kumar, lead investigator of the trial, says he hopes that researchers will be able to prove that it is safe to treat these patients and get them to a sustained MRD-negative status. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 22, 2016 Category: Hematology Source Type: news

Upcoming Consensus on Minimal Residual Disease (MRD) Testing Confirms Black Swan Approach
The IMF's Black Swan Research Initiative® moves a major step forward with the imminent publication of new myeloma response criteria using minimal residual disease (MRD) testing. In his blog this week, IMF Chairman Dr. Brian Durie explains the significance of this consensus by more than 200 top myeloma experts and why it confirms the Black Swan approach, and offers a snapshot of MRD testing for patients wondering if it's ready for “prime time.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 15, 2016 Category: Hematology Source Type: news

iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma)
In this video, Dr. Sirgurdur Kristinsson of the University of Iceland describes the exciting new Black Swan Research Initiative® study, iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma). As part of the iStopMM study, 140,000 Icelanders over the age of 40 will have their blood samples tested for the precursor to multiple myeloma, or MGUS (monoclonal gammopathy of undetermined significance). If they test for MGUS, they are given the option to take part in a randomized clinical trial to treat or prevent the progression of MM. Dr. Kristinnson explains the four aims of this groundbreaking study in this video.&...
Source: International Myeloma Foundation - July 15, 2016 Category: Hematology Source Type: news

Big Data Sharing Is Fundamental to Our Research Success
Vice President Joe Biden's recent National Cancer Moonshot Summit concluded with the announcement of a “shared data initiative.” “The IMF's International Myeloma Working Group (IMWG) has been gathering and sharing data from all major myeloma institutions globally for more than a decade,” writes IMF Chairman Dr. Brian Durie in his blog this week. “And our Black Swan Research Initiative® is actively sharing data on our path to find the cure.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 8, 2016 Category: Hematology Source Type: news

View the slides and replay for the IMF's Post ASCO/EHA/IMWG Recap Teleconference!
Please join Brian G.M. Durie, MD as he explains what's new and exciting from the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG). (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 7, 2016 Category: Hematology Source Type: news

View the slides for the IMF's Post ASCO/EHA/IMWG Recap Teleconference!
Please join Brian G.M. Durie, MD as he explains what's new and exciting from the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG). (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 7, 2016 Category: Hematology Source Type: news

DARZALEX ™ (daratumumab) Approved by Health Canada as the First Human Anti-CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma
Janssen Inc. announces Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving DARZALEX ™ (daratumumab) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD. Health Canada approved this product on the conditi on that Janssen Inc. carries out confirmatory trials to verify the clinical benefit of DARZALEX™. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 6, 2016 Category: Hematology Source Type: news

DARZALEX™ (daratumumab) Approved by Health Canada as the First Human Anti-CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma
Janssen Inc. announces Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving DARZALEX™ (daratumumab) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD. Health Canada approved this product on the condition that Janssen Inc. carries out confirmatory trials to verify the clinical benefit of DARZALEX™. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 6, 2016 Category: Hematology Source Type: news

FDA Approves New Kyprolis & #174; (carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) —a division of the European Medicines Agency—recommended a change to the terms of the marketing authorization for Kyprolis & #174; (carfilzomib) for the treatment of relapsed multiple myeloma. As of July 3, 2016, CHMP approved Kyprolis in combination with dexamethasone alone to treat adult patients who have received at least one prior therapy. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 5, 2016 Category: Hematology Source Type: news

FDA Approves New Kyprolis® (carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP)—a division of the European Medicines Agency—recommended a change to the terms of the marketing authorization for Kyprolis® (carfilzomib) for the treatment of relapsed multiple myeloma. As of July 3, 2016, CHMP approved Kyprolis in combination with dexamethasone alone to treat adult patients who have received at least one prior therapy. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 5, 2016 Category: Hematology Source Type: news

IMF Educates on Dangers of Limiting Access to Myeloma Treatment Options
Robin Tuohy, IMF Senior Director of Support Groups, and her husband Michael Tuohy, a 16-year myeloma survivor and active patient advocate, appeared at a congressional briefing in Washington DC this week. They shared the perspective of patients and caregivers on the myeloma treatment guidelines that were recently proposed by the Institute for Clinical and Economic Review (ICER). The briefing was organized by the Partnership to Improve Patient Care (PIPC). Robin spoke of her family's journey in coping with Michael's illness. She also addressed how the proposals recommended in the ICER Report to the Center for Medicare and Me...
Source: International Myeloma Foundation - June 24, 2016 Category: Hematology Source Type: news

Register Today for the IMF's Post ASCO/EHA/IMWG Recap Teleconference!
Please join Brian G.M. Durie, MD as he explains what's new and exciting from the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG). (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 23, 2016 Category: Hematology Source Type: news

Dr. Brian Durie: "ICER Blinks and Patients Benefit"
IMF Chairman Dr. Brian Durie calls the much-awaited Final Report from the Institute for Clinical and Economic Review (ICER) “less of a report than an admission that they do not have the expertise to adequately assess the complexities of new myeloma therapies.” In his blog this week, Dr. Durie notes that the report defers to the expertise of both doctors and patient advocates, and, importantly, that the International Myeloma Working Group has already launched an inclusive project to create treatment guidelines that can transform the cost/payer landscape. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 16, 2016 Category: Hematology Source Type: news

Robin Tuohy's testimony at CEPAC on Treatment Options for Relapsed and Refractory Myeloma
On May 26, 2016, the International Myeloma Foundation’sSenior Director of Support Groups and spouse of Michael Tuohy, a sixteen-year myeloma survivor, testified at the Comparative Effectiveness Public Advisory Council’s Public Meeting (CEPAC) on Treatment Options for Relapsed and Refractory Myeloma. In her compelling testimony, Robin shared how her husband Michael’s survival as a myeloma patient may not have been possible without access to a clinical trial, an [and] oral therapy regimen, he has been on for the past eleven years. She pointed out, “Today we are able to treat myeloma in seque...
Source: International Myeloma Foundation - June 10, 2016 Category: Hematology Source Type: news

Pre-EHA Chinese Hematologist Round Table
IMF in cooperation with Xian-Janssen (XJP) is hosting the Pre-EHA Chinese Hematologists Round Table at the Hotel Scandic Copenhagen in Copenhagen, Denmark.   (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 10, 2016 Category: Hematology Source Type: news

The IMWG Conference Series "Making Sense of Treatment" < br > 7th IMWG Summit | June 9, 2016
Drs. Brian GM Durie, Joseph Mikhael,Paul Richardson , and Maria Victoria Mateos discusses the latest news and trends in the treatment of Multiple Myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 9, 2016 Category: Hematology Source Type: news

The IMWG Conference Series "Making Sense of Treatment" 7th IMWG Summit | June 9, 2016
Drs. Brian GM Durie, Joseph Mikhael,Paul Richardson, and Maria Victoria Mateos discusses the latest news and trends in the treatment of Multiple Myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 9, 2016 Category: Hematology Source Type: news

Living Well with Myeloma: < br > What you Need to Know to Overcome Side Effects from Novel Therapies
Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN Cleveland Clinic Taussig Cancer Institute Multiple Myeloma Program Cleveland, OH &nbsp; Kevin Brigle, PhD, NP VCUHS Massey Cancer Center Richmond, VA &nbsp; (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 5, 2016 Category: Hematology Source Type: news

Living Well with Myeloma: What you Need to Know to Overcome Side Effects from Novel Therapies
Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN Cleveland Clinic Taussig Cancer Institute Multiple Myeloma Program Cleveland, OH   Kevin Brigle, PhD, NP VCUHS Massey Cancer Center Richmond, VA   (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 5, 2016 Category: Hematology Source Type: news

International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit
Addressing Rising Cost of Myeloma Treatments to Be a Key Focus (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 2, 2016 Category: Hematology Source Type: news

International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit
Addressing Rising Cost of Myeloma Treatments to Be a Key Focus (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 2, 2016 Category: Hematology Source Type: news

Pierre S. Sayad Joins IMF as Senior Vice President, Global Medical Affairs and Strategic Partnerships
(Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 1, 2016 Category: Hematology Source Type: news

International Myeloma Foundation Honors Dr. S. Vincent Rajkumar With the 2016 Robert A. Kyle Lifetime Achievement Award
Given in Recognition of Significant Contributions to Myeloma Research and Patient Care (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 31, 2016 Category: Hematology Source Type: news

International Myeloma Foundation Honors Dr. S. Vincent Rajkumar With the 2016 Robert A. Kyle Lifetime Achievement Award
Given in Recognition of Significant Contributions to Myeloma Research and Patient Care (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 31, 2016 Category: Hematology Source Type: news

ASCO 2016: More Excitement About Daratumumab (Darzalex & #174;) and Tremendous Interest in Value and Costs
As usual, far fewer myeloma-related abstracts will be presented at next month's annual meeting of the American Society of Clinical Oncology (ASCO) than are presented at the annual meeting of the American Society of Hematology (ASH) each December. But, writes IMF Chairman Dr. Brian Durie in his blog this week, the results of the Phase III CASTOR study have created some excitement, and the subjects of “cost” and “value” in cancer treatment are definitely in the air! To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news

ASCO 2016: More Excitement About Daratumumab (Darzalex®) and Tremendous Interest in Value and Costs
As usual, far fewer myeloma-related abstracts will be presented at next month's annual meeting of the American Society of Clinical Oncology (ASCO) than are presented at the annual meeting of the American Society of Hematology (ASH) each December. But, writes IMF Chairman Dr. Brian Durie in his blog this week, the results of the Phase III CASTOR study have created some excitement, and the subjects of “cost” and “value” in cancer treatment are definitely in the air! To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news

International Myeloma Foundation (IMF) Says Controversial Drug Cost Report Could Limit Patient Access to Optimal Treatment
 IMF Raises Red Flags in Advance of May 26 Hearing, Offers Alternate Approach (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 24, 2016 Category: Hematology Source Type: news

Janssen's Single-Agent DARZALEX & #174; (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)
The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Darzalex (daratumumab) for the treatment of adults with relapsed and refractory multiple myeloma. Darzalex is to be used in patients whose previous treatment included a proteasome inhibitor and an immunomodulatory agent (other types of cancer medicines) and whose disease worsened after treatment. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 23, 2016 Category: Hematology Source Type: news

Janssen's Single-Agent DARZALEX® (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)
The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Darzalex (daratumumab) for the treatment of adults with relapsed and refractory multiple myeloma. Darzalex is to be used in patients whose previous treatment included a proteasome inhibitor and an immunomodulatory agent (other types of cancer medicines) and whose disease worsened after treatment. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 23, 2016 Category: Hematology Source Type: news

What Is a Life Worth?
QALY stands for the quality of an adjusted life year. It is a ratio that economists use to determine the quality and quantity of life in order to ascertain the cost of medical interventions. But, as IMF Chairman Dr. Brian Durie asks, where do these numbers come from? In his blog this week, Dr. Durie calls for regulatory agencies to respect patients' rights to the best care possible by not assessing them based on an arbirtrary number such as QALY. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 20, 2016 Category: Hematology Source Type: news

Obesity a Risk Factor for Myeloma in African Americans
A new study has found an association between body mass index (BMI) and the risk for multiple myeloma among African Americans in the United States. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 15, 2016 Category: Hematology Source Type: news

What is this new Black Swan project called iStopMM?
In this week’s video, Dr. Brian Durie describes how the iStopMM study aims to prevent myeloma in the entire adult population of adults who are age 40 or over in Iceland. BOTTOM LINE: While a seemingly lofty goal, iStopMM may bridge the pathway to eliminating myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 14, 2016 Category: Hematology Source Type: news